ArticleScientific reports2026
Neuropeptides neurotensin and substance P accelerate diabetic wound healing by modulating immunity and the skin microbiome.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic foot ulcers (DFUs) are a common and debilitating complication of diabetes mellitus, typified by impaired healing, persistent inflammation, and skin microbiota dysbiosis. Although some neuropeptides are immunomodulatory, their effects on skin microbiota and wound resolution remain largely unexplored. We examined the therapeutic potential of the neuropeptides neurotensin (NT) and substance P (SP) in reshaping inflammatory and microbial dynamics and accelerating wound closure in a healthy and streptozotocin-induced diabetic mice model. Full-thickness cutaneous wounds were induced on both groups, followed by daily topical applications of saline (CT), NT, or SP. Wound closure was monitored and changes in skin bacterial communities characterized using next-generation sequencing. Wound tissue samples were collected for immunohistochemical analysis. Topical application of NT or SP significantly accelerated wound healing, with the most pronounced effects in diabetic animals. Both neuropeptides reduced the number of pro-inflammatory cells, lowering M1 macrophages in diabetic wounds from 16.4 ± 4 to 12.1 ± 3 with NT and 10.9 ± 3 with SP, while increasing M2 macrophages from 11.6 ± 4 to 18.1 ± 4 (NT) and 21.6 ± 5 (SP). SP exerted the most pronounced immunomodulatory effect, normalizing the M1/M2 ratio and reducing the number of CD3⁺ T cells (12.4 ± 3) and neutrophils (12.1 ± 3) to levels comparable to non-diabetic skin. Concurrently, SP treatment induced substantial microbiota remodeling in diabetic wounds, reducing Staphylococcus by circa 34%, Aerococcaceae_unclassified by 6.8%, Aerococcus by 1.5% and nearly eliminating Weissella. These reductions were accompanied by an over twofold increase in commensal genera (Lactobacillus, Micrococcaceae_unclassified, Actinobacteria_unclassified), shifting the microbial community toward a more non-diabetic profile. Our findings suggest that NT and especially SP, enhance diabetic wound healing through dual local immunomodulation and microbiota restructuring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.